Back to Newsroom

Arrowhead Receives Regulatory Clearance for ARC-AAT Phase 1 in the United Kingdom and New Zealand

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory permission in the United Kingdom and New Zealand to proceed with Part B of its Phase 1 study of ARC-AAT, Arrowhead’s RNAi-based drug candidate for the treatment of liver disease associated with the rare genetic disorder alpha-1 antitrypsin deficiency (AATD). The Phase 1 study is currently enrolling patients at a single center in Australia and, pending approval from ethics committees, the company intends to begin recruiting patients at additional sites in the United Kingdom and New Zealand. Arrowhead expects to complete enrollment by the end of 2015.

Click here to read more